Related Experiment Video
Updated: Dec 21, 2025
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
462
Recent Advances in Managing Acute Lymphoblastic Leukemia.
Daniel J DeAngelo1, Elias Jabbour2, Anjali Advani3
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Summary
Advances in understanding acute lymphoblastic leukemia (ALL) genetics improve risk stratification and minimal residual disease monitoring. Emerging therapies offer new hope for relapsed/refractory and older ALL patients facing poor outcomes.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Acute lymphoblastic leukemia (ALL) involves chromosomal translocations and mutations.
- Pediatric regimens and tyrosine kinase inhibitors have improved outcomes in certain groups.
- Older patients and those with relapsed/refractory ALL face significant challenges due to poor-risk biology and treatment tolerance.
Purpose of the Study:
- To review the evolving genetic landscape of ALL.
- To discuss emerging therapeutic options for challenging ALL patient populations.
Main Methods:
- Review of current literature on ALL genetics and treatment strategies.
- Analysis of advancements in next-generation sequencing for genetic risk stratification.
- Evaluation of minimal residual disease (MRD) measurement techniques.
Main Results:
- Next-generation sequencing has revolutionized the understanding of ALL genetics.
- Genetic risk stratification and MRD monitoring provide better tools for guiding postremission therapy.
- Improved survival in young adults and Philadelphia chromosome-positive ALL patients noted.
Conclusions:
- Despite advances, older patients and those with relapsed/refractory ALL have poor prognoses.
- Emerging therapies are crucial for improving outcomes in these difficult-to-treat ALL populations.
- Continued research into ALL genetics and novel treatments is essential.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
729
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
729
02:57Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K